

## Capital

The approved Capital Resource Limit (CRL) value issued on 5<sup>th</sup> January is £50.502m. The approved CRL value includes Discretionary Capital, schemes under the All-Wales Capital Programme and new/renewal IFRS 16 Leases.

## Outturn Performance

The forecast outturn shows an overspend position of £0.140m. Allocations are anticipated on the following schemes, which will provide a balanced position.

| Scheme  | £m    | Narrative         |
|---|-------|-------------------|
| IRCF – Cymmer / Croeserw Health & Wellbeing Centre Fees | 0.140 | Funding approved. |

The following allocations are classed as risks.

| Scheme   | £m / Risk Level | Narrative   |
|--|-----------------|---|
| Positron Emission Tomography (PET) Service, Singleton Hospital | 0.494 / High    | <p>There has been further slippage on this scheme due to design queries covering the main AHU and the potential impact on the overall scheme if the space was not sufficient.</p> <p>The contractor undertook a further review of the AHU design to ensure the plant could be accommodated within the design. As part of the review the plant walkways were deemed unsafe and had to be replaced. These had to be designed and installed to ensure the area was safe to work.</p> <p>These works have consequently resulted in additional programme slippage which will be managed by the Health Board.</p> |

| Scheme   | £m / Risk Level | Narrative  |
|--|-----------------|--|
| Replacement Diagnostic and Treatment Equipment 2025-26 | 0.594 / High    | <p>The variance in Table I is £0.906m but £0.312m of this variance is not a Capital scheme underspend, it represents the cost of mobile hire in relation to the CT Scanner at Morriston which is accounted for as a revenue cost.</p> <p>However, there have been ongoing design delays in relation to the Interventional Radiology (IR) - Fluoroscopy 2 programme at Morriston Hospital resulting in slippage which is to be managed by the Health Board.</p>   |
| DPIF – RISP  | 0.270 / Medium  | <p>The RISP programme continues to report a lack of confidence in relation to Philips’ ability to deliver against a revised plan of a 23rd February 2026 go-live based upon current performance, escalations continue, including a request to meet their Managing Director in January.</p> <p>Data migration has progressed with testing and checks on scanner connectivity planned throughout January and into February. The risk of slipping against the programme remains, since other Health Boards go-live before Swansea Bay and they are advising of slippages within their programmes which will have a consequential impact on ours. The Project Team is closely monitoring the critical path and dependencies with DHCW, Soliton and Philips. The Fuji PACS contract has been extended to March 2027 as mitigation.</p> <p>Initial charges are due for payment upon stable operations, therefore any delays will potentially impact upon the health boards requirement to utilise both the Owned Asset Capital funding</p> |

| Scheme | £m / Risk Level | Narrative  |
|--------|-----------------|--|
|        |                 | <p>and the IFRS 16 Capital funding in 2025-26. In terms of Owned Asset funding, the current view is that £270k is at risk of not being spent if we do not achieve go-live on 23<sup>rd</sup> February 2026.</p> <p>A further update will be provided if there is any contractual change which confirms definite slippage into next year.</p> <p>The IFRS 16 RISP considerations are described in the narrative of Table Q.</p> |

All other schemes are low risk, and any variances are linked to planned contributions from discretionary and in some instances payback of prior year fees.

### Capital Disposals

There are no further property disposals planned for 2025/26.